Eli Lilly & Co. has started a Phase 3 trial of its experimental antibody-based COVID-19 drug in nursing homes and other long-term care facilities, testing whether the drug reduces the infection rate at facilities where residents or staff have recently tested positive for the new coronavirus. The study involves Eli Lilly driving specially modified RVs to newly infected nursing homes and injecting its COVID-19 drug, code-named LY-CoV555, in volunteers, The Wall Street Journal reports. The company said its drug may get government approval by the end of 2020.
Eli Lilly is already testing its antibody treatment, developed with Canadian biotech AbCellera Biologics, in hospitals on COVID-19 patents with mild and more severe cases. Researchers essentially cloned antibodies from one of the first U.S. patients to recover from COVID-19, hoping those proteins help the immune system fight the virus or prevent it from taking hold. If Eli Lilly's drug or another like it proves safe and effective, public health experts say it might serve as a bridge until a vaccine is available.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Harry Potter is coming to TV: what we know about new HBO showThe Explainer Cillian Murphy as Voldemort? Paapa Essiedu as Snape? All the latest on the huge new series shooting in the UK this summer
-
Dairy milk, once maligned, is making a comebackUnder the Radar Sales of dairy milk were up 2% in 2024
-
6 solid travel mugs and bottles for all excursionsThe Week Recommends Stay hydrated on the go
-
Trump's China tariffs start after Canada, Mexico pausesSpeed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
-
Chinese AI chatbot's rise slams US tech stocksSpeed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
-
US port strike averted with tentative labor dealSpeed Read The strike could have shut down major ports from Texas to Maine
-
Biden expected to block Japanese bid for US SteelSpeed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
-
Judges block $25B Kroger-Albertsons mergerSpeed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
-
Rupert Murdoch loses 'Succession' court battleSpeed Read Murdoch wanted to give full control of his empire to son Lachlan, ensuring Fox News' right-wing editorial slant
-
Bitcoin surges above $100k in post-election rallySpeed Read Investors are betting that the incoming Trump administration will embrace crypto
-
Enron mystery: 'sick joke' or serious revival?Speed Read 23 years after its bankruptcy filing, the Texas energy firm has announced its resurrection
